New Additions to Drugs.com for 2024
The following 19 drugs were added to the Drugs.com database in 2024.
Rezenopy
May 1, 2024 - Rezenopy (naloxone hydrochloride) is a nasal spray that may be used for the temporary treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond in adults or children. Follow up with emergency medical help right away after giving the first dose of Rezenopy nasal spray, even if the person wakes up.
Libervant
May 1, 2024 - Libervant (diazepam) is an oral benzodiazepine film that may be used short-term to treat children aged 2 to 5 years with seizure clusters (also known as “acute repetitive seizures”) that are different from their usual seizure pattern. Libervant is placed on the inside of a child’s cheek (buccally).
Beqvez
May 1, 2024 - Beqvez (fidanacogene elaparvovec-dzkt) is an one-time, injectable, viral vector-based gene therapy that may be used to treat moderate to severe hemophilia B (congenital factor IX deficiency) in adult males who currently use factor IX prophylaxis therapy, or have current or a history of life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and, do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
Xolremdi
Apr 30, 2024 - Xolremdi (mavorixafor) is an oral CXC chemokine receptor 4 antagonist that may be used to increase the number of circulating mature neutrophils and lymphocytes in adults and children 12 years of age and older with WHIM syndrome.
Pivya
Apr 29, 2024 - Pivya (pivmecillinam) is an oral penicillin-type antibiotic that may be used to treat uncomplicated urinary tract infections (UTIs) in females aged 18 years and older that are caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Xromi
Apr 23, 2024 - Xromi (hydroxyurea) is an oral solution that may be used to reduce the frequency of painful crises and reduce the need for blood transfusions in children aged 6 months to less than 2 years old, with sickle cell anemia who have recurrent moderate to severe painful crises.
Risvan
Apr 5, 2024 - Risvan (risperidone intramuscular) is an extended-release injectable, atypical, antipsychotic that is given by a healthcare provider once a month and may be used to treat schizophrenia in adults.
Voydeya
Apr 2, 2024 - Voydeya (danicopan) is an oral complement factor D inhibitor that may be used to treat extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) as add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) when patients have had an insufficient response to these treatments.
Winrevair
Mar 28, 2024 - Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered subcutaneously and may be used to treat adults with pulmonary arterial hypertension (PAH, WHO Group 1). Winrevair can improve your ability to exercise, improve your ability to perform normal activities with fewer symptoms and reduce the risk of your physical condition and symptoms worsening.
Pemgarda
Mar 26, 2024 - Pemgarda (pemivibart) is an unapproved, injectable, antiviral, human monoclonal antibody that has received emergency use authorization (EUA) for the prevention of COVID-19 in high-risk immunocompromised adults and adolescents 12 years of age and older who weigh at least 40kg. Candidates cannot be currently infected with SARS-CoV-2 or have had a known recent exposure to an individual infected with SARS-CoV-2, and must be moderately to severely immune compromised due to a medical condition (such as blood cancer) or receipt of immunosuppressive medications or treatments (such as an organ transplant) and be unlikely to mount an adequate immune response to COVID-19 vaccination.
Tryvio
Mar 25, 2024 - Tryvio (aprocitentan) is a once-daily, dual oral ERA that may be used to treat high blood pressure that is not adequately controlled by other high blood pressure medications. It is used in combination with other antihypertensives and reportedly has a low potential for drug interactions.
Edurant and Edurant Ped
Mar 19, 2024 - Edurant (rilpivirine tablets) and Edurant Ped (rilpivirine tablets for oral suspension) may be used to treat previously untreated HIV-1 infection in adults and children aged 2 years of age and older, weighing at least 14 kg, with HIV-1 RNA less than or equal to 100,000 copies/mL. They are used in combination with other antiretroviral agents.
Tevimbra
Mar 15, 2024 - Tevimbra (tislelizumab-jsgr) is a cancer medicine that is given intravenously (into a vein) that may be used to treat adults with esophageal squamous cell carcinoma that has spread to other parts of the body (metastatic) or cannot be surgically removed. Tevimbra is given after prior treatments that did not include a PD-L 1 inhibitor.
Rezdiffra
Mar 15, 2024 - Rezdiffra (resmetirom) is an oral (taken by mouth) THR-beta agonist that may be used to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. It should be used alongside diet and exercise.
Tyenne
Mar 10, 2024 - Tyenne (tocilizumab-aazg) is an injectable interleukin-6 (IL-6) receptor antagonist that may be used to treat adults with moderately to severely active rheumatoid arthritis or Giant Cell Arteritis (GCA), or people aged 2 years and older with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or active systemic juvenile idiopathic arthritis (SJIA). Tyenne is a biosimilar to Actemra and has both subcutaneous and IV formulations.
Wyost
Mar 6, 2024 - Wyost (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) by a healthcare provider for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; the treatment of giant cell tumor of the bone that cannot be removed by surgery or when surgery is too risky in adults and adolescents who have fully grown; and the treatment of high calcium levels associated with cancer that has not responded to bisphosphonates. Wyost is an interchangeable biosimilar to Xgeva (denosumab).
Letybo
Mar 4, 2024 - Letybo (letibotulinumtoxinA-wlbg) is injected into muscles to temporarily improve the appearance of moderate to severe brow furrows (glabellar lines) in adults. These frown lines are typically associated with corrugator and/or procerus muscle activity.
Simlandi
Feb 26, 2024 - Simlandi (adalimumab-ryvk) is a tumor necrosis factor (TNF) blocker interchangeable biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Amtagvi
Feb 19, 2024 - Amtagvi (lifileucel) is a type of medicine called “tumor-derived autologous T cell immunotherapy” that is given as an infusion into your vein (usually in a hospital). It may be used to treat adults with melanoma that cannot be surgically removed or has spread to other parts of the body AND has not responded or has stopped responding to a PD-1 blocking drug either by itself or in a combination AND, if BRAF V600 mutation-positive, has not responded to a BRAF inhibitor with or without a MEK inhibitor.